Search

Your search keyword '"Gianni Mura"' showing total 5 results
Start Over Author "Gianni Mura" Search Limiters Peer Reviewed
5 results on '"Gianni Mura"'

1. Looking for a strategy in treating peritoneal gastric cancer carcinomatosis: an Italian multicenter Gastric Cancer Research group’s analysis

Author

Luigina Graziosi, Elisabetta Marino, Maria Bencivenga, Alessia D’Ignazio, Leonardo Solaini, Silvia Ministrini, Michela Caprioli, Michele Sacco, Daniele Marrelli, Gianni Mura, Maurizio Degiuli, Paolo Morgagni, Guido Alberto Massimo Tiberio, Giovanni De Manzoni, Franco Roviello, and Annibale Donini

Subjects
Gastric cancer, Peritoneal carcinomatosis, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The present study provides a snapshot of Italian patients with peritoneal metastasis from gastric cancer treated by surgery in Italian centers belonging to the Italian Research Group on Gastric Cancer. Prognostic factors affecting survival in such cohort of patients were evaluated with the final aim to identify patients who may benefit from radical intent surgery. Methods It is a multicentric retrospective study based on a prospectively collected database including demographics, clinical, surgical, pathological, and follow-up data of patients with gastric cancer and synchronous macroscopic peritoneal metastases. Patients were surgically treated from January 2005 to January 2017. We focused on patients with macroscopic peritoneal carcinomatosis (PC) treated with upfront surgery in order to provide homogeneous evidences. Results Our results show that patients with peritoneal carcinomatosis cannot be considered all lost. Strictly selected cases (R0/R1 and P1 patients) could benefit from an aggressive surgical approach performing an extended lymphadenectomy and HIPEC treatment. Conclusion The main result of the study is that GC patients with limited peritoneal involvement can have a survival benefit from a surgery with “radical oncological intent”, that means extended lymphadenectomy and R0 resection. The retrospective nature of this study is an important bias, and for this reason, we have started a prospective multicentric study including Italian stage IV patients that hopefully will give us more answers.

Published
2021
Full Text
View/download PDF

2. Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study

Author

Maria Antonietta Mazzei, Giulio Bagnacci, Francesco Gentili, Andrea Nigri, Veronica Pelini, Carla Vindigni, Francesco Giuseppe Mazzei, Gian Luca Baiocchi, Frida Pittiani, Paolo Morgagni, Enrico Petrella, Gianni Mura, Beatrice Verdelli, Maria Bencivenga, Simone Giacopuzzi, Daniele Marrelli, Franco Roviello, and Luca Volterrani

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Aim. To investigate the role of maximum tumour diameter (D-max) reduction rate at CT examination in predicting histopathological tumour regression grade (TRG according to the Becker grade), after neoadjuvant chemotherapy (NAC), in patients with resectable advanced gastric cancer (AGC). Materials and Methods. Eighty-six patients (53 M, mean age 62.1 years) with resectable AGC (≥T3 or N+), treated with NAC and radical surgery, were enrolled from 5 centres of the Italian Research Group for Gastric Cancer (GIRCG). Staging and restaging CT and histological results were retrospectively reviewed. CT examinations were contrast enhanced, and the stomach was previously distended. The D-max was measured using 2D software and compared with Becker TRG. Statistical data were obtained using “R” software. Results. The interobserver agreement was good/very good. Becker TRG was predicted by CT with a sensitivity and specificity, respectively, of 97.3% and 90.9% for Becker 1 (D-max reduction rate > 65.1%), 76.4% and 80% for Becker 3 (D-max reduction rate

Published
2018
Full Text
View/download PDF

3. Some Concerns from a Radiological Point of View. Comment on Huang et al. Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone

Author

Maria Antonietta, Mazzei, Giulio, Bagnacci, Armando, Perrella, Nunzia, Di Meglio, Stefania Angela, Piccioni, Francesco, Bloise, Daniele, Marrelli, Carlo, Milandri, and Gianni, Mura

Abstract

We read, with great interest, the article by Huang Ruo-Yi and colleagues entitled "Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone", published on 1 April 2022 [...].

Published
2022

4. Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial

Author

Luigina Graziosi, Uberto Fumagalli Romario, Maria Bencivenga, Franco Roviello, Oriana Nanni, Daniele Marrelli, Giovanni de Manzoni, Silvia Bozzarelli, Francesca Steccanella, Stefano Rausei, Massimo Framarini, Giovanni Sgroi, Annibale Donini, Stefano Santi, Luca Saragoni, Andrea Rinnovati, Giorgio Ercolani, Lorenza Rimassa, Flavia Foca, Paolo Morgagni, Ilaria Proserpio, Valentina Mengardo, Giovanni Luca Frassineti, Carlo Milandri, Manlio Monti, Sarah Molfino, Emilio Parma, Roberto Petrioli, Gian Luca Baiocchi, Gianni Mura, Dino Amadori, Linda Valmorri, Alessandra Signorini, Verena De Angelis, J. Viganò, Silvia Brugnatelli, Monti M., Morgagni P., Nanni O., Framarini M., Saragoni L., Marrelli D., Roviello F., Petrioli R., Romario U.F., Rimassa L., Bozzarelli S., Donini A., Graziosi L., De Angelis V., De Manzoni G., Bencivenga M., Mengardo V., Parma E., Milandri C., Mura G., Signorini A., Baiocchi G., Molfino S., Sgroi G., Steccanella F., Rausei S., Proserpio I., Vigano J., Brugnatelli S., Rinnovati A., Santi S., Ercolani G., Foca F., Valmorri L., Amadori D., and Frassineti G.L.

Subjects
0301 basic medicine, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, lcsh:RC254-282, Gastroenterology, Article, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Chemotherapy, Medicine, Perioperative, Progression-free survival, Preoperative, Gastric cancer, business.industry, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Oxaliplatin, Regimen, 030104 developmental biology, Oncology, Docetaxel, 030220 oncology & carcinogenesis, business, Febrile neutropenia, medicine.drug
Abstract

Docetaxel associated with oxaliplatin and 5-fluorouracil (FLOT) has been reported as the best perioperative treatment for gastric cancer. However, there is still some debate about the most appropriate number and timing of chemotherapy cycles. In this randomized multicenter phase II study, patients with resectable gastric cancer were staged through laparoscopy and peritoneal lavage cytology, and randomly assigned (1:1) to either four cycles of neoadjuvant chemotherapy (arm A) or two preoperative + two postoperative cycles of docetaxel, oxaliplatin, and capecitabine (DOC) chemotherapy (arm B). The primary endpoint was to assess the percentage of patients receiving all the planned preoperative or perioperative chemotherapeutic cycles. Ninety-one patients were enrolled between September 2010 and August 2016. The treatment was well tolerated in both arms. Thirty-three (71.7%) and 24 (53.3%) patients completed the planned cycles in arms A and B, respectively (p = 0.066), reporting an odds ratio for early interruption of treatment of 0.45 (95% confidence interval (CI): 0.18&ndash, 1.07). Resection was curative in 39 (88.6%) arm A patients and 35 (83.3%) arm B patients. Five-year progression-free survival (PFS) was 51.2% (95% CI: 34.2&ndash, 65.8) in arm A and 40.3% (95% CI: 28.9&ndash, 55.2) in arm B (p = 0.300). Five-year survival was 58.5% (95% CI: 41.3&ndash, 72.2) and 53.9% (95% CI: 35.5&ndash, 69.3) (p = 0.883) in arms A and B, respectively. The planned treatment was more frequently completed and was more active, albeit not significantly, in the neoadjuvant arm than in the perioperative group.

Published
2020
Full Text
View/download PDF

5. The sentinel node biopsy in early gastric cancer: a preliminary study

Author

Gianni Mura, Alessio Vagliasindi, Massimo Framarini, Giorgio Maria Verdecchia, Paolo Mazza, and Gabriele Solfrini

Subjects
Male, Oncology, medicine.medical_specialty, medicine.medical_treatment, Breast cancer, Gastrectomy, Stomach Neoplasms, Internal medicine, Biopsy, medicine, Humans, Coloring Agents, Aged, Neoplasm Staging, Aged, 80 and over, medicine.diagnostic_test, Sentinel Lymph Node Biopsy, business.industry, Melanoma, Middle Aged, Sentinel node, medicine.disease, Early Gastric Cancer, Cardiothoracic surgery, Lymphatic Metastasis, Feasibility Studies, Lymph Node Excision, Female, Surgery, Lymphadenectomy, Radiology, Radiopharmaceuticals, business
Abstract

Sentinel node biopsy is currently used in surgery of malignant melanoma and breast cancer. The feasibility of sentinel node mapping in gastrointestinal cancers and its diagnostic sensitivity is unclear. It could be of particular value in the management of early gastric cancer in which radical D2 lymphadenectomy may be unnecessary. From January 2004 to June 2005, ten patients with preoperative diagnosis of early gastric cancer and no nodal involvement (cT1N0) were submitted to sentinel node biopsy using the dual mapping procedure with endoscopic blue dye and 99mTc radio colloid injection. All the patients underwent standard radical gastrectomy and D2 lymphadenectomy. The resected nodes were evaluated by routine (hematoxylin–eosin) histopathological examination; the sentinel (blue or hot) nodes, in addition, were evaluated with immunohistochemistry for cytokeratin. The detection rate of this procedure was 100%. The preliminary results and perspectives for feasibility of sentinel node biopsy and its accuracy in predicting the nodal status in early gastric cancer are discussed.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results